Series A generates $9.6mm for Arsanis
Executive Summary
Start-up infectious disease firm Arsanis Inc. brought in $9.6mm via its Series A equity financing to Polaris Venture Partners, SV Life Sciences, OrbiMed Advisors--each contributes one board member--and four undisclosed backers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice